Followers | 49 |
Posts | 3878 |
Boards Moderated | 0 |
Alias Born | 09/14/2007 |
Sunday, July 22, 2018 7:31:37 PM
PAVMZ – publicly traded series Z warrant has an exercise price of $1.60 with the following terms – you can also view this information that was included in an SEC filing on June 1, 2018 regarding Form 423B3 Prospectus – page 5 - http://ir.pavm.com/sec-filings:
Each Series Z Warrant, listed for trading on Nasdaq under the symbol “PAVMZ”, entitles the holder to purchase one share of common stock at an exercise price of $1.60 per share from the date on which the Series Z Warrant is issued through its expiration on April 30, 2024, or earlier upon certain redemption provisions. Commencing on the first anniversary of the issuance date of the Series Z Warrants, the Company may redeem the outstanding Series Z Warrants, at the Company’s option, in whole or in part, at a price of $0.01 per warrant: at any time while the warrants are exercisable; upon a minimum of 30 days’ prior written notice of redemption; if, and only if, the volume weighted average closing price of the Company’s common stock equals or exceeds $9.00 (subject-to adjustment) for any 20 out of 30 consecutive trading days ending three Business Days before the Company issues its notice of redemption, and provided the average daily trading volume in the stock is at least 20,000 shares per day; and, if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants.
PAVMW – publicly traded series W warrant has an exercise price of $5.00 with the following terms – as more fully described in our Annual Report on Form 10-K filed with the SEC
· The Series W Warrants have an exercise price of $5.00 per share, with such exercise price not subject to further adjustment, except in the event of stock dividends, stock splits or similar events affecting the common stock, and became exercisable on October 28, 2016 and expire on January 29, 2022, or earlier upon redemption by the Company, as discussed below.
Commencing April 28, 2017, the Company may redeem the outstanding Series W Warrants (other than those outstanding prior to the IPO held by the Company’s management, founders, and members thereof, but including the warrants held by the initial investors), at the Company’s option, in whole or in part, at a price of $0.01 per warrant: at any time while the warrants are exercisable; upon a minimum of 30 days’ prior written notice of redemption; if, and only if, the volume weighted average price of the Company’s common stock equals or exceeds $10.00 (subject-to adjustment) for any 20 consecutive trading days ending three business days before the Company issues its notice of redemption, and provided the average daily trading volume in the stock is at least 20,000 shares per day; and, if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants. The right to exercise will be forfeited unless the IPO Warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of an IPO Warrant will have no further rights except to receive the redemption price for such holder’s IPO Warrant upon surrender of such warrant.
Dennis McGrath
Chief Financial Officer
NASDAQ: PAVM
One Grand Central Place, Suite 4600
New York, NY 10165
Tel: 212-949-4319
mobile: 609-432-6861
Recent PAVM News
- PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements • PR Newswire (US) • 09/16/2024 08:30:00 PM
- Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress • PR Newswire (US) • 09/10/2024 11:56:00 AM
- Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health • PR Newswire (US) • 09/03/2024 11:51:00 AM
- Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer • PR Newswire (US) • 08/20/2024 12:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:18:18 PM
- The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer • PR Newswire (US) • 08/13/2024 12:16:00 PM
- PAVmed Provides Business Update and Second Quarter 2024 Financial Results • PR Newswire (US) • 08/13/2024 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:08:39 PM
- Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results • PR Newswire (US) • 08/12/2024 12:07:00 PM
- Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event • PR Newswire (US) • 08/08/2024 12:31:00 PM
- Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing • PR Newswire (US) • 08/06/2024 12:15:00 PM
- Lucid Diagnostics to Participate in Upcoming Investor Conferences • PR Newswire (US) • 08/05/2024 12:15:00 PM
- PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 • PR Newswire (US) • 07/30/2024 12:15:00 PM
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 • PR Newswire (US) • 07/29/2024 12:15:00 PM
- Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume • PR Newswire (US) • 07/23/2024 12:01:00 PM
- Lucid Diagnostics Launches New Corporate Website • PR Newswire (US) • 07/11/2024 12:31:00 PM
- Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population • PR Newswire (US) • 07/02/2024 11:55:00 AM
- PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute • PR Newswire (US) • 06/13/2024 11:58:00 AM
- 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing • PR Newswire (US) • 06/12/2024 12:05:00 PM
- PAVmed Provides Business Update and First Quarter 2024 Financial Results • PR Newswire (US) • 05/14/2024 12:43:00 AM
- Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results • PR Newswire (US) • 05/13/2024 12:00:00 PM
- Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall • PR Newswire (US) • 05/09/2024 11:49:00 AM
- Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors • PR Newswire (US) • 05/07/2024 11:39:00 AM
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 • PR Newswire (US) • 05/03/2024 12:35:00 PM
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 • PR Newswire (US) • 05/02/2024 12:35:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM